Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 12/20 | 0.71 |
| ▸ | MTOR | P42345 | 6/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270835 | 0.90 | FYN (0.82) | MAP3K11MTORFYN | |
| SCHEMBL4164637 | 0.90 | MTOR (0.62) | MAP3K11MTORFYN | |
| SCHEMBL4167768 | 0.89 | MTOR (0.61) | MAP3K11MTORFYN | |
| SCHEMBL4169485 | 0.89 | MTOR (0.64) | MAP3K11MTORFYN | |
| SCHEMBL4268394 | 0.89 | MTOR (0.66) | MAP3K11MTORFYN | |
| SCHEMBL13657423 | 0.88 | MTOR (0.63) | MAP3K11MTORFYN | |
| SCHEMBL4266986 | 0.85 | MTOR (0.74) | MAP3K11MTORFYN | |
| SCHEMBL4013123 | 0.85 | MTOR (0.69) | MAP3K11MTORFYN | |
| SCHEMBL4268568 | 0.85 | FYN (0.69) | MAP3K11MTORFYN | |
| SCHEMBL4268540 | 0.83 | MTOR (0.67) | MAP3K11MTORFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | claimed |
| EP-1796467-A4 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | EP | claimed |
| EP-1796467-A2 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | claimed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | claimed |
| WO-2006036883-A2 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | claimed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | AURKA, AURKC, AURKB | MAP3K11 116/4885MTOR 414/4885FYN 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.